Remifentanil

Remifentanil

File:Remifentanil.png
Clinical data
Routes of administration	Intravenous
ATC code	N01AH06 (WHO)
Legal status
Legal status	US: Schedule II legal_NL = List I
Pharmacokinetic data
Bioavailability	Not applicable (intravenous administration)
Protein binding	70% (bound to plasma proteins)
Metabolism	cleaved by non-specific plasma and tissue esterases
Elimination half-life	1-20 minutes
Identifiers
IUPAC name methyl 1-(2-methoxycarbonylethyl)-4-(phenyl-propanoyl-amino) -piperidine-4-carboxylate
CAS Number	132875-61-7
PubChem CID	60815
DrugBank	APRD01216
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C20H28N2O5
Molar mass	376.447 g/mol
Melting point	5 °C (41 °F)

Remifentanil (marketed by Abbott as Ultiva®) is a potent ultra short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anaesthetic. Remifentanil is used for sedation as well as combined with other medications for use in general anesthesia. The use of remifentanil has made possible the use of high dose opioid and low dose hypnotic anesthesia, due to synergism between remifentanil and various hypnotic drugs and volatile anesthetics.

Dosing

It is administered in the form remifentanil hydrochloride and in adults is given as an intravenous infusion in doses ranging from 0.1 microgram per kilogram per minute to 0.5 (µg/kg)/min. Children may require higher infusion rates (up to 1.0 (µg/kg)/min). Doses listed in the package insert from its manufacturer are much higher than those used in actual clinical practice. The clinically useful infusion rates are 0.025-0.1 (µg/kg)/min for sedation (rates adjusted to age of patient, severity of their illness and invasiveness of surgical procedure). Small amounts of other sedative medications are usually co-administered with remifentanil to produce sedation. Clinically useful infusion rates in general anesthesia vary but are usually 0.1-1 µg/kg/min[1]. Remifentanil is also used in computer controlled infusion pumps in a concept called target controlled infusion or TCI. A target plasma concentration is entered in microgram/ml into the pump and it thereafter keeps the infusion at an optimal speed. Two dosing modes are therefor common when using remifentanil clinically, the µg/kg/min and microgram/ml when using target controlled infusions.

Metabolism

Unlike other synthetic opioids which are hepatically metabolised, remifentanil has an ester linkage which undergoes rapid hydrolysis by non-specific tissue and plasma esterases. This means that accumulation does not occur with remifentanil and its context-sensitive half-life remains at 4 minutes after a 4 hour infusion.

Remifentanil is metabolised to a compound (remifentanil acid) which has 1/4600 the potency of the parent compound.

Due to its quick metabolism and short effects remifentanil has opened up new possibilities in anesthesia. When remifentanil is used together with a hypnotic drug (i.e. one that produces sleep) it can be used in relative high doses. This is because remifentanil will be rapidly eliminated from the blood plasma on termination of the remifentanil infusion, hence the effects of the drug will quickly dissipate even after very long infusions. Due to synergism between remifentanil and hypnotic drugs (such as propofol) the dose of the hypnotic can be substantially reduced. This leads often to more haemodynamic stablity during surgery and a quicker post-operative recovery time.

Side-effects

Remifentanil is a specific μ-receptor agonist. Hence, it causes a reduction in sympathetic nervous system tone, respiratory depression and analgesia. The drug's effects include a dose-dependent decrease in heart rate and arterial pressure and respiratory rate and tidal volume. Muscle rigidity is sometimes noted.

The most common side effects reported by patients receiving this medication are a sense of extreme "dizziness" (often short lived, a common side effect of other fast-acting synthetic phenylpiperidine narcotics such as fentanyl and alfentanil) and intense itching (pruritus), often around the face. These side effects are often controlled by either altering the administered dose (decreasing or in some cases, increasing the dose) or by administering other sedatives that allow the patient to tolerate or lose awareness of the side effect.

Because pruritus is due to excessive serum histamine levels, antihistamines such as diphenhydramine (benadryl) are often co-administered. This is done with care, however, as excessive sedation may occur.

Nausea can occur as a side effect of remifentanil, however, it is usually transient in nature due to the drug's short half life which rapidly removes it from the patient's circulation once the infusion is terminated.

Potency

Remifentanil has a similar potency to fentanyl

Circumventing Naltrexone

Remifentanil has been used with some success to circumvent naltrexone in patients who are in need of pain management.

Administration

Remifentanil can be administered as part of a TIVA (Total Intravenous Anaesthesia technique) using TCA. Target Controlled Anaesthesia. The short context-sensitive half-life allows the plasma level or effector site level to be achieved quickly and recovery to occur quickly.

Induction levels of 4 pg/ml are commonly used.

Regulation

In Hong Kong, Remifentanil is regulated under Schedule 1 of Hong Kong's Chapter 134 Dangerous Drugs Ordinance. It can only be used legally by health professionals and for university research purporses. The substance can be given by pharmacists under a prescription. Anyone who supply the substance without prescription can be fined $10000 (HKD). The penalty for trafficking or manufacturing the substance is a $5,000,000 (HKD) fine and life imprisonment. Possession of the substance for consumption without license from the Department of Health is illegal with a $1,000,000 (HKD) fine and/or 7 years of jail time.